An Approach to Rapidly Identify a Functional & Developable Bispecific Antibody

Hear from Abzena’s Director of Protein Engineering, Dr Arron Hearn, as he presents at this year’s Antibody Engineering & Therapeutics Conference on how to identify a functional and developable bispecific antibody.

Presentation Overview:
Combining single function antibodies into a bi-specific or multi specific format can present unique challenges. Stoichiometry, overall layout (IgG like, asymmetrical) and affinity can all play a key role in the success of a design with the desired activity and therapeutic developability. From multiple examples, it is clear that each bispecific development program should be treated as unique and that strategies are required to identify the optimal format. Abzena has developed a screening cascade which first places a strong focus on intelligent bispecific design which considers avidity, spacing as well as the use of different technologies. In combination with in silico analysis to identify and engineer the best partners for developability, we can provide screening on a minimal number of smart designs. By leveraging unparalleled expertise in antibody production, purification, analytics and functional bioassays, we can rapidly identify and advance the most promising bispecific candidates.

Access the Discussion Board